Tech Company Financing Transactions
Spero Therapeutics Funding Round
On 3/9/2017, Spero Therapeutics raised $51.7 million in Seed funding from GV, RA Capital and Rock Springs Capital.
Transaction Overview
Company Name
Announced On
3/9/2017
Transaction Type
Venture Equity
Amount
$51,700,000
Round
Seed
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Spero's unique pipeline of antibacterials focused on drug-resistant bacterial infections.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
675 Massachusetts Ave. 14th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
Spero Therapeutics' (Nasdaq: SPRO) vision is to find, develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease using a unique business and drug discovery model. Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ankit Mahadevia
Chief Financial Officer
Joel Sendek
Chief Medical Officer
David Melnick
Chief Operating Officer
Cristina Larkin
Chief Scientific Officer
Thomas Parr
VP - Bus. Development
Timothy Keutzer
VP - Bus. Development
Scott Peterson
VP - Finance
Steve Garbacz
VP - R & D
Troy Lister
VP - Regulatory Affairs
Carol Waldo
Browse more venture capital transactions:
Prev: 3/9/2017: Kinsa venture capital transaction
Next: 3/9/2017: Fluxx venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs